US FDA declines to approve Atara Biotherapeutics' cancer therapy
1. FDA rejected Atara's tabelecleucel cancer therapy application. 2. This will delay potential revenue and development for ATRA.
FAQ
Why Very Bearish?
FDA rejections can significantly impact a biotech's stock price, as seen with other firms like Amarin, which dropped after similar setbacks.
How important is it?
FDA decisions directly affect biotech companies' prospects and market confidence.
Why Long Term?
The failure to receive FDA approval can prolong time to market, affecting future revenue streams.